Therapeutic potential of TAS-115 in 3D breast cancer models
Source abstract
Abstract
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. TAS-115, a multi-receptor tyrosine kinase inhibitor, has not previously been evaluated in TNBC. Here, we investigated its therapeutic effects alone and in combination with doxorubicin (DOXO), using three-dimensional heterotypic spheroid models, including free-standing, bioprinted static, and perfused systems. TAS-115 significantly reduced cell proliferation and viability, enhanced apoptosis, and suppressed c-mesenchymal-epithelial transition/hepatocyte growth factor and PI3K/Akt/mTOR signaling. Combined treatment with DOXO further amplified these effects. In perfused bioprinted models, TAS-115 markedly inhibited tumor cell migration, highlighting its potential to limit metastatic behavior. These findings identify TAS-115 as a promising therapeutic strategy for TNBC, either as a monotherapy or in combination with chemotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Cells and Metastasis · 3D Printing in Biomedical Research · Cellular Mechanics and Interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Understanding breast cancer as a global health concern10.1259/BJR.20211033 ↗
2. Crosstalk of inflammatory cytokines within the breast tumor microenvironment10.3390/ijms24044002 ↗
3. Cell adhesion and matrix stiffness: coordinating cancer cell invasion and metastasis10.3389/fonc.2018.00145 ↗
4. Regulation of breast cancer metastasis signaling by miRNAs10.1007/s10555-020-09905-7 ↗
5. Pre-metastatic niche: from revealing the molecular and cellular mechanisms to the clinical applications in breast cancer metastasis10.7150/thno.82700 ↗
6. Macrophage-secreted S100A4 supports breast cancer metastasis by remodeling the extracellular matrix in the premetastatic niche10.1155/2022/9895504 ↗
7. Unlocking c-MET: a comprehensive journey into targeted therapies for breast cancer10.1016/j.canlet.2024.216780 ↗
8. c-Met expression in renal cell carcinoma with bone metastases10.1016/j.jbo.2020.100315 ↗
9. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma10.1186/s12885-017-3324-3 ↗
10. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors10.1007/s10637-019-00859-4 ↗
11. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer10.1111/cas.12301 ↗
12. Reversal of c-MET-mediated resistance to cytotoxic anticancer drugs by a novel c-MET inhibitor TAS-115
13. Chemotherapeutics and CAR-T cell-based immunotherapeutics screening on a 3D bioprinted vascularized breast tumor model10.1002/adfm.202203966 ↗
14. E-Cadherin: a conductor of cellular signaling10.1016/j.ceb.2025.102559 ↗
15. Membrane-induced 2D phase separation of the focal adhesion protein talin10.1038/s41467-024-49222-z ↗
16. Regulation of matrix metalloproteinase-13 in cancer: signaling pathways and non-coding RNAs in tumor progression and therapeutic targeting10.5306/wjco.v16.i6.105996 ↗
17. Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence10.3389/fmolb.2022.836417 ↗
18. SIRT1/FOXO signaling pathway in breast cancer progression and metastasis10.3390/ijms231810227 ↗
19. c-Met as a target for personalized therapy10.4137/tog.s30534 ↗
20. Triple-negative breast cancer molecular subtyping and treatment progress10.1186/s13058-020-01296-5 ↗
21. Tumor microenvironment: the role of the tumor stroma in cancer10.1002/jcb.21159 ↗
22. The clinical and functional significance of c-Met in breast cancer: a review10.1186/s13058-015-0547-6 ↗
23. Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2
24. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile10.1158/1535-7163.MCT-13-0459 ↗
25. TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma10.1002/2211-5463.12827 ↗
26. Three-dimensional printing of Hela cells for cervical tumor model in vitro10.1088/1758-5082/6/3/035001 ↗
27. Triple inhibition of EGFR, met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation10.1097/JTO.0000000000000170 ↗
28. RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A110.1038/s41375-019-0656-9 ↗
29. Virulence profile: Frederick M Ausubel10.4161/viru.26579 ↗
30. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer10.1007/s13346-024-01648-0 ↗
31. A functional polymorphism of inhibin alpha subunit at miR-181b-1-3p-binding site regulates proliferation and apoptosis of chicken ovarian granular cells10.1007/s00441-020-03356-w ↗
32. Fibroblasts in cancer: unity in heterogeneity10.1016/j.cell.2023.03.016 ↗
33. Stromal fibroblasts in cancer initiation and progression10.1038/nature03096 ↗
34. Drug resistance and the solid tumor microenvironment10.1093/jnci/djm135 ↗
35. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling10.1186/s12967-018-1660-y ↗
36. Cardiac fibroblasts10.1007/s00399-018-0553-3 ↗